Infinity Pharmaceuticals | INFI - Cost Of Sales


Infinity Pharmaceuticals reported $352K in Cost of Sales for its fiscal quarter ending in June of 2023.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cipla INR 29.1B 1.16B Dec/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.65M 10K Sep/2025
CSL USD 1.79B 2.15B Jun/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Grifols EUR 1.32B 22.75M Sep/2025
Incyte USD 121.18M 22.18M Dec/2025
Infinity Pharmaceuticals USD 352K 89K Jun/2023
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
J&J USD 7.97B 689M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
TG Therapeutics USD 28.09M 9.15M Sep/2025